Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 110B 396M 348M 325M 298M 558M 37.93B 572M 3.85B 1.51B 18.77B 1.49B 1.45B 64.89B P/E 2026 *
10.2x
P/E 2027 * 8.67x
Enterprise Value 110B 396M 348M 325M 298M 558M 37.93B 572M 3.85B 1.51B 18.77B 1.49B 1.45B 64.89B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 1.47x
Free-Float
16.89%
Yield 2026 *
5.25%
Yield 2027 * 5.95%
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
05-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
04-06 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
03-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
03-26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-24 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-02 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
25-08-26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-1.26%
1 week+0.23%
Current month-5.47%
1 month-3.90%
3 months+0.24%
6 months-16.59%
Current year-10.21%
1 week 337.5
Extreme 337.5
361.75
1 month 337.5
Extreme 337.5
393
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 2020-02-29
Director of Finance/CFO - 2021-05-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 2011-05-06
Director/Board Member - 2018-12-04
Director/Board Member 72 2020-04-01
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%+0.23%-16.99%+341.42% 401M
-2.66%-0.56%+55.14%+159.43% 1,079B
-3.20%-0.12%+54.83%+54.58% 640B
-2.18%+0.45%+36.33%+72.54% 465B
-2.70%+0.66%+35.52%+30.01% 353B
-1.92%-0.23%+34.03%+39.85% 301B
-2.77%+0.36%+10.74%+13.83% 271B
-2.11%+3.23%+1.74%-39.45% 228B
-1.33%+3.08%+27.06%+63.54% 209B
-1.59%-0.52%+13.44%+70.97% 165B
Average -2.31%+4.50%+25.18%+80.67% 371.01B
Weighted average by Cap. -2.65%+4.86%+39.20%+76.32%

Financials

2026 *2027 *
Net sales 68.81B 248M 218M 203M 187M 349M 23.73B 358M 2.41B 942M 11.74B 930M 910M 40.6B 74.58B 269M 236M 220M 202M 378M 25.72B 388M 2.61B 1.02B 12.73B 1.01B 986M 44B
Net income 10.49B 37.77M 33.19M 30.98M 28.43M 53.22M 3.62B 54.53M 367M 144M 1.79B 142M 139M 6.19B 12.42B 44.72M 39.3M 36.68M 33.66M 63.02M 4.28B 64.57M 435M 170M 2.12B 168M 164M 7.33B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
26-07-29 PKR 350.00 -1.26% 86,849
26-07-28 PKR 354.45 -0.27% 239,005
26-07-27 PKR 355.42 +3.73% 211,518
26-07-24 PKR 342.65 -0.58% 117,513
26-07-23 PKR 344.65 -1.30% 159,994
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
350.00PKR
Average target price
517.50PKR
Spread / Average Target
+47.86%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock